CNS Pharmaceuticals Inc. has announced promising scientific research results concerning their lead program, TPI 287, at the Brain Tumor Biotech Summit. TPI 287, an abeotaxane, is in development for treating glioblastoma multiforme (GBM) and has been granted Orphan Drug Designation by the FDA for treating gliomas, pediatric neuroblastoma, and progressive supranuclear palsy. Unlike other taxanes that struggle to penetrate the blood-brain barrier $(BBB.UK)$, TPI 287 has shown potential in crossing the BBB to treat central nervous system tumors. In a Phase 1 trial, when used in combination with bevacizumab, TPI 287 demonstrated efficacy with 3 Complete Responses and 9 Partial Responses among 23 evaluable glioblastoma patients. These findings highlight the drug candidate's promise as a novel treatment option for brain tumors.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。